Asian Pacific Journal of Cancer Prevention

Asian Pacific Journal of Cancer Prevention (아시아태평양암예방학회)
권호 표지
DOI QR코드

DOI QR Code

Relationship Between the SER Treatment Period and Prognosis of Patients with Small Cell Lung Cancer

  • Xiao, Xiao-Guang (Department of Oncology, Tongji Hospital, Tongji Medical College of Huazhong University of Science and Technology) ;
  • Wang, Shu-Jing (Department of Oncology, Tongji Hospital, Tongji Medical College of Huazhong University of Science and Technology) ;
  • Hu, Li-Ya (Department of Oncology, Tongji Hospital, Tongji Medical College of Huazhong University of Science and Technology) ;
  • Chu, Qian (Department of Oncology, Tongji Hospital, Tongji Medical College of Huazhong University of Science and Technology) ;
  • Wei, Yao (Department of Oncology, Tongji Hospital, Tongji Medical College of Huazhong University of Science and Technology) ;
  • Li, Yang (Department of Oncology, Tongji Hospital, Tongji Medical College of Huazhong University of Science and Technology) ;
  • Mei, Qi (Department of Oncology, Tongji Hospital, Tongji Medical College of Huazhong University of Science and Technology) ;
  • Chen, Yuan (Department of Oncology, Tongji Hospital, Tongji Medical College of Huazhong University of Science and Technology)
  • Published : 2014.08.15
Download PDF
⟨ Previous Next ⟩

Abstract

Purpose: To explore the relationship between SER (time between the start of any treatment and the end of radiation therapy) and the survival of patients with limited-stage small cell lung cancer. Materials and Methods: Between 2008 and 2013, 135 cases of limited-stage small cell lung cancer (LS-SCLC) treated with consecutively curative chemoradiotherapy were included in this retrospective analysis. In terms of SER, patients were divided into early radiotherapy group (SER<30 days, n=76) and late radiotherapy group ($SER{\geq}30$ days, n=59) with a cut-off of SER 30 days. Outcomes of the two groups were compared for overall survival. Results: For all analyzable patients, median follow-up time was 23.8 months and median overall survival time was 16.8 months. Although there was no significant differences in distant metastasis free survival between the two groups, patients in early radiotherapy group had a significantly better PFS (p=0.003) and OS (p=0.000). Conclusions: A short SER may be a good prognostic factor for LD-SCLC patients treated with concurrent chemoradiotherapy.

Keywords

References

  1. Amini A, Byers LA, Welsh JW, et al (2014). Progress in the management of limited-stage small cell lung cancer.Cancer, 120, 790-8. https://doi.org/10.1002/cncr.28505
  2. Brade AM, Tannock IF (2006). Scheduling of radiation and chemotherapy for limited-stage small-cell lung cancer: Repopulation as a cause of treatment failure? J Clin Oncol, 24, 1020-2. https://doi.org/10.1200/JCO.2005.04.9676
  3. Cai S, Shi A, Yu R, et al (2014). Feasibility of omitting clinical target volume for limited-disease small cell lung cancer treated with chemotherapy and intensity-modulated radiotherapy. Radiat Oncol, 9, 112-7. https://doi.org/10.1186/1748-717X-9-112
  4. Chen YT, Feng B, Chen LB (2012). Update of research on drug resistance in small cell lung cancer chemotherapy. Asian Pac J Cancer Prev, 13, 3577-81. https://doi.org/10.7314/APJCP.2012.13.8.3577
  5. Davis AJ, Tannock IF (2002). Tumor physiology and resistance to chemotherapy: repopulation and drug penetration. Cancer Treat Res, 112, 1-6. https://doi.org/10.1007/978-1-4615-1173-1_1
  6. De-Ruysscher D, Wanders S, Boersma L, et al (2004). A novel time factor, the SER (Start of any treatment and the End of Radiotherapy), is predictive for local control and survival in a systematic overview of combined chest radiotherapy and chemotherapy for limited stage small cell lung cancer. Radiother Oncol, 3, 143-9.
  7. De-Ruysscher D, Pijls-Johannesma M, Bentzen SM, et al (2006). Time between the first day of chemotherapy and the last day of chest radiation is the most important predictor of survival in limited-disease small-cell lung cancer. J Clin Oncol, 24, 1057-63. https://doi.org/10.1200/JCO.2005.02.9793
  8. De-Ruysscher D, Vansteenkiste J, Kester A, et al (2007). Timing of chest radiotherapy in patients with limited stage small cell lung cancer: a systematic review and meta-analysis of randomized controlled trials. Cancer Treat Rev, 33, 461-73. https://doi.org/10.1016/j.ctrv.2007.03.002
  9. Feng ZX, Zhao LJ, Guan Y ,et al (2013). Metastatic characteristics of lymph node in supraclavicular zone and radiotherapy target volume for limited-stage small cell lung cancer.Zhonghua Yi Xue Za Zhi, 93,1476-8.
  10. Govindan R, Page N, Morgensztern D, et al (2006). Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: analysis of the surveillance, epidemiologic, and end results database. J Clin Oncol, 24, 4539-44. https://doi.org/10.1200/JCO.2005.04.4859
  11. Ha IB, Jeong BK, Jeong H, et al (2013). Effect of early chemoradiotherapy in patients with limited stage small cell lung cancer. Radiat Oncol J, 31, 185-90. https://doi.org/10.3857/roj.2013.31.4.185
  12. Han TJ, Kim HJ, Wu HG, et al (2012). Comparison of treatment outcomes between involved-field and elective nodal irradiation in limited-stage small cell lung cancer. Jpn J Clin Oncol, 42, 948-54. https://doi.org/10.1093/jjco/hys114
  13. Huncharek M, McGarry R (2004). A meta-analysis of the timing of chest irradiation in the combined modality treatment of limited-stage small cell lung cancer. Oncologist, 9, 665-72. https://doi.org/10.1634/theoncologist.9-6-665
  14. Jassem J ( 2007). The role of radiotherapy in lung cancer: where is the evidence? Radiother Oncol, 83, 203-13. https://doi.org/10.1016/j.radonc.2007.04.004
  15. Jeremic B, Shibamoto Y, Acimovic L, et al (2007). Initial versus delayed accelerated hyperfractionated radiation therapy and concurrent chemotherapy in limited small-cell lung cancer: a randomized study. J Clin Oncol, 15, 893-900.
  16. Kalemkerian GP (2011). Advances in the treatment of small-cell lung cancer. Semin Respir Crit Care Med , 32, 94-101. https://doi.org/10.1055/s-0031-1272873
  17. Le-Pechoux C, Dunant A, Senan S, et al (2009). Standard-dose versus higher-dose prophylactic cranial irradiation (PCI) in patients with limited-stage small-cell lung cancer in complete remission after chemotherapy and thoracic radiotherapy: a randomised clinical trial. Lancet Oncol, 10, 467-74. https://doi.org/10.1016/S1470-2045(09)70101-9
  18. Manapov F, Klocking S, Niyazi M, et al (2013). Timing of failure in limited disease (stage I-III) small-cell lung cancer patients treated with chemoradiotherapy: a retrospective analysis. Tumori, 99, 656-60.
  19. Murray N, Coy P, Pater JL, et al (2003). Importance of timing for thoracic irradiation in the combined modality treatment of limited-stage small-cell lung cancer. J Clin Oncol, 11, 336-44.
  20. Paumier A, Le Pechoux C (2010). Radiotherapy in small-cell lung cancer: where should it go? Lung Cancer, 69, 133-40. https://doi.org/10.1016/j.lungcan.2010.04.019
  21. Perry MC (2006). Thoracic radiation therapy in limited stage small-cell lung cancer: timing is everything. isn't it? J Clin Oncol, 24, 3815-6. https://doi.org/10.1200/JCO.2006.07.2827
  22. Simon GR, Turrisi A (2007). Management of small cell lung cancer: ACCP evidence-based clinical practice guidelines (2nd edition). Chest, 132, 324-39. https://doi.org/10.1378/chest.07-1385
  23. Socinski MA, Bogart JA (2007). Limited-stage small-cell lung cancer: the current status of combined-modality therapy. J Clin Oncol, 25, 4137-45. https://doi.org/10.1200/JCO.2007.11.5303
  24. Spiro SG, James LE, Rudd RM, et al (2006). Early compared with late radiotherapy in combined modality treatment for limited disease small-cell lung cancer: a London Lung Cancer Group multicenter randomized clinical trial and meta-analysis. J Clin Oncol, 24, 3823-30. https://doi.org/10.1200/JCO.2005.05.3181
  25. Stinchcombe TE, Gore EM (2010). Limited-stage small cell lung cancer: current chemoradiotherapy treatment paradigms. Oncologist, 15, 187-9. https://doi.org/10.1634/theoncologist.2009-0298
  26. Tsujino K, Kurata T, Kawaguchi T, et al (2014). Role of consolidation chemotherapy after concurrent chemoradiotherapy in locally advanced non-small-cell lung cancer. J Thorac Oncol, 9, 7-8 https://doi.org/10.1097/JTO.0000000000000028
  27. Viani GA, Boin AC, Ikeda VY, et al (2012). Thirty years of prophylactic cranial irradiation in patients with small cell lung cancer: a meta-analysis of randomized clinical trials. J Bras Pneumol, 38, 372-81. https://doi.org/10.1590/S1806-37132012000300013
  28. Wu BS, Hu Y, Sun J, et al (2014). Analysis on the characteristics and prognosis of pulmonary neuroendocrine tumors. Asian Pac J Cancer Prev, 15, 2205-10. https://doi.org/10.7314/APJCP.2014.15.5.2205
  29. Zhang J, Qi HW, Zheng H, et al (2014). Etoposide-cisplatin alternating with vinorelbine-cisplatin versus etoposide-Cisplatin alone in patients with extensive disease combined with small cell lung cancer. Asian Pac J Cancer Prev, 15, 4159-63. https://doi.org/10.7314/APJCP.2014.15.10.4159

Cited by

  1. Clinical features and prognostic factors of small cell lung cancer: A retrospective study in 148 patients vol.36, pp.6, 2016, https://doi.org/10.1007/s11596-016-1684-6